Anti-ULBP1 Antibody, clone 6B17 ZooMAb® Rabbit Monoclonal
SIGMA/ZRB1032 - recombinant, expressed in HEK 293 cells
Synonym: UL16-binding protein 1;ALCAN-beta;NKG2D ligand 1;N2DL-
Product Type: Chemical
antibody form | purified antibody |
antibody product type | primary antibodies |
biological source | rabbit |
clone | 6B17, recombinant monoclonal |
conjugate | unconjugated |
description | recombinant, expressed in HEK 293 cells |
enhanced validation | recombinant expression Learn more about Antibody Enhanced Validation ![]() |
epitope sequence | N-terminal |
form | lyophilized |
greener alternative category | Aligned ![]() |
greener alternative product characteristics | Waste Prevention Designing Safer Chemicals Design for Energy Efficiency Learn more about the Principles of Green Chemistry ![]() |
isotype | IgG |
mol wt | calculated mol wt 28.0 kDa |
observed mol wt ~25 kDa | |
packaging | antibody small pack of 25 μL |
product line | ZooMAb® learn more ![]() |
Protein ID accession no. | NP_079494.1 ![]() ![]() |
purified by | using Protein A |
Quality Level | 200 ![]() |
recombinant | expressed in HEK 293 cells |
shipped in | ambient |
species reactivity | human |
species reactivity (predicted by homology) | chimpanzee |
storage temp. | 2-8°C |
technique(s) | affinity binding assay: suitable |
immunocytochemistry: suitable | |
western blot: suitable | |
UniProt accession no. | Q9BZM6 ![]() ![]() |
Application: | Quality Control Testing Evaluated by Western Blotting with human recombinant ULBP1. Western Blotting Analysis: A 1:1,000 dilution of this antibody detected human recombinant ULBP1. Tested applications Affinity Binding Assay: A representative lot of this antibody bound ULBP1 with a KD of 1.0 x 10-8 in an affinity binding assay. Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected ULBP1in K562 cells. Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user |
Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
General description: | We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here ![]() |
General description: | ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them. |
Immunogen: | KLH-conjugated linear peptide corresponding to 18 amino acids from the N-terminal region of human UL16-binding protein 1. |
Legal Information: | ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany |
Physical form: | Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL. |
Reconstitution: | 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type. |
Specificity: | Clone 6B17 is a Rabbit recombinant monoclonal antibody that specifically detects UL16-binding protein 1. It targets an epitope within 18 amino acids from the N-terminal region. |
Storage and Stability: | Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws. |
Target description: | UL16-binding protein 1 (UniProt: Q9BZM6; also known as ALCAN-beta, NKG2D ligand 1, N2DL-1, NKG2DL1, Retinoic acid early transcript 1I) is encoded by the ULBP1 (also known as N2DL1, RAET1I) gene (Gene ID: 80329) in human. The UL16-binding proteins are a novel family of MHC class I-related, GPI-anchored, cell surface proteins that lack an 3 domain, and do not associate with β2-microglobulin. ULBP1 was first identified based on its ability to bind to the human CMV (HCMV) glycoprotein UL16. It is synthesized with a signal peptide (aa 1-25) and a propeptide (aa 217-244) that are subsequently cleaved off to produce the mature protein (aa 26-216). It is expressed in T-cells, B-cells, erythroleukemia cell lines and in a wide range of tissues. It is also found in fetal heart, brain, lung, and liver. It binds and activates the natural killer group 2 member D (NKG2D) receptor and mediates natural killer cell cytotoxicity. In CMV-infected cells, it interacts with the viral glycoprotein UL16 and this interaction causes ULBP1 retention in the endoplasmic reticulum and cis-Golgi and prevents binding to and activation of NKG2D, which provides CMV with an immune evasion mechanism. ULBP1 expressed on the tumor cell surface can also bind to the NKG2D receptor presenting on NK cells and CD8+ T and T cells. Patients with NKG2D expression in gastric tumor exhibit significantly longer overall survival compared to those without NKG2D expression in tumors. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Kamei, R., et al. (2018). Oncology Lett. 15(1); 747-754; Sutherland, CL., et al. (2002). J. Immunol. 168(2); 671-679). |
Storage Temp. | 2-8°C |